Stocky turns companies like KUBOTA PHARMACEUTICAL HLDGS CO into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. 4596.T scores just 12/100 on Value Compounder metrics, signaling weak fundamentals and limited margin of safety. Leadership alignment is poor at 36.3/100, reflecting misaligned incentives or governance concerns that increase execution risk. While the Vulnerability Index is low, the combination of weak value creation and weak governance oversight creates asymmetric downside.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for KUBOTA PHARMACEUTICAL HLDGS CO :
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 16/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates KUBOTA PHARMACEUTICAL HLDGS CO (4596.T) at 16/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. 4596.T scores just 12/100 on Value Compounder metrics, signaling weak fundamentals and limited margin of safety. Leadership alignment is poor at 36.3/100, reflecting misaligned incentives or governance concerns that increase executio
4596.T's current Stocky Verdict is 16/100, placing it in the "Avoid" band. This composite combines a 12/100 Compounder score, 36/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for KUBOTA PHARMACEUTICAL HLDGS CO yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
KUBOTA PHARMACEUTICAL HLDGS CO scores 36/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
KUBOTA PHARMACEUTICAL HLDGS CO 's Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to KUBOTA PHARMACEUTICAL HLDGS CO .
Sign up free and unlock the full analysis on 4596.T — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for 4596.T in the app.
